Innealta Capital’s Fate Therapeutics FATE Stock Holding History

Innealta Capital’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9	Closed	-$30	–	682
2024 Q2	$30	Buy	+9	New	+$39	﹤0.01%	1784

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Innealta Capital's FATE Position: Q3 2024 in Review

Innealta Capital sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 9 shares — an estimated $30 sold.

Innealta Capital first reported a position in FATE in Q2 2024 and held it in 1 quarter. The position peaked at $30 in Q2 2024. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

Innealta Capital reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 9 Fate Therapeutics shares in Q3 2024, an estimated $30.
Innealta Capital first reported a position in Fate Therapeutics in Q2 2024 and held it in 1 quarter.
Innealta Capital's Fate Therapeutics position peaked at $30 in Q2 2024.
164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.